Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 232,206,034 papers from all fields of science
Search
Sign In
Create Free Account
simtuzumab
A humanized monoclonal antibody against lysyl oxidase-like 2 (LOXL2), with potential antineoplastic activity. Anti-LOXL2 monoclonal antibody GS 6624…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Narrower (2)
AB0024
GS-6624
Broader (1)
Antibodies, Monoclonal, Humanized
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis
A. Khan
,
Nimra Iftikhar
,
+11 authors
F. Anwer
Blood
2018
Corpus ID: 199027776
Introduction Drugs that target activating mutations of Janus Kinase 2 (JAK2) have been the backbone of myelofibrosis (MF…
Expand
2018
2018
Simtuzumab Is Ineffective for Treatment of Primary Sclerosing Cholangitis
A. Zaman
2018
Corpus ID: 86521096
Currently there is no effective treatment for primary sclerosing cholangitis (PSC). Because lysyl oxidase like-2 (LOXL2) might be…
Expand
2017
2017
Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study.
A. Joshi
,
Jenny Y. Zhang
,
Liang Fang
Contemporary Clinical Trials
2017
Corpus ID: 20909007
2017
2017
Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial
A. Muir
,
Z. Goodman
,
+13 authors
B. Eksteen
2017
Corpus ID: 57628481
Review
2017
Review
2017
A quick overview to the early phase clinical trials of Simtuzumab®: Are we loosing the most promising anti-fibrotic product?
A. Altinbas
Medical Hypotheses
2017
Corpus ID: 38470985
Review
2017
Review
2017
Idiopathic Pulmonary Fibrosis: What Is the Best Treatment?
Xiaoping Wu
,
R. Kaner
,
F. Martinez
2017
Corpus ID: 80132859
Idiopathic pulmonary fibrosis (IPF) is a disease of chronic progressive interstitial pneumonia limited to the lungs. There is…
Expand
2016
2016
LATE-BREAKING ABSTRACT: Simtuzumab in idiopathic pulmonary fibrosis: Results of a randomized clinical trial
G. Raghu
,
K. Brown
,
+12 authors
T. O'Riordan
2016
Corpus ID: 79441854
Simtuzumab is a monoclonal antibody against the lysl-oxidase like-2 (LOXL2) enzyme. 544 subjects with idiopathic pulmonary…
Expand
2014
2014
New approaches tackle rising pancreatic cancer rates.
V. Brower
Journal of the National Cancer Institute
2014
Corpus ID: 40388242
Taking the immunomodulator simtuzumab with gemcitabine did not statistically significantly increase progression-free survival in…
Expand
2013
2013
Glaucoma The Role of LOX and LOXL 2 in Scar Formation After Glaucoma Surgery
T. Bergen
,
D. Marshall
,
+5 authors
I. Stalmans
2013
Corpus ID: 33898167
Citation: Van Bergen T, Marshall D, Van de Veire S, et al. The role of LOX and LOXL2 in scar formation after glaucoma surgery…
Expand
2013
2013
A phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of simtuzumab (GS-6624) combined with gemcitabine as first-line treatment for metastatic pancreatic…
A. Benson
,
Zung Thai
,
+4 authors
J. Bendell
2013
Corpus ID: 79129108
TPS4149 Background: Lysyl oxidase-like molecule 2 (LOXL2) is an extracellular matrix enzyme that catalyzes the covalent cross…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE